Since TFPI-2 hypermethylation is an early event in tumorigenesis, the authors concluded that selectively targeting ribosylation of H3R117 deficiency may block tumorigenesis in CRC [109]. The gene discussed is TFPI2; the disease is colorectal carcinoma.